Protein Drugs Market By Type | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Protein Drugs Market
Protein Drugs Market: By Type (Antibody Drugs, Peptide Hormones, Blood Products, and Enzymes) & By Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)
Report Code : HCR 0354
Updated Date: 27 July, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Protein Drugs Market – Market Overview
2. Executive Summary 
3. Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Protein Drugs Market– Market Forces
   4.1. Drivers
      4.1.1. Development the arena of proteomics and nanotechnology
      4.1.2. Growing incidences of chronic and autoimmune diseases
   4.2. Restraints
      4.2.1. Higher cost of research and development  
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Protein Drugs Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Protein Drugs Market, By Type
   6.1. Antibody Drugs
   6.2. Peptide Hormones
   6.3. Blood Products
   6.4. Enzymes 
7. Protein Drugs Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America 
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Protein Drugs – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. Eli Lilly
   9.2. Abbott Laboratories
   9.3. UCB Group
   9.4. Schering-Plough Corporation
   9.5. Genentech Inc.
   9.6. Johnson & Johnson
   9.7. Bristol-Myers Squibb
   9.8. Novo Nordisk
   9.9. Biogen Idec
   9.10. Dendreon Corporation
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
There is a shift in focus from molecular drugs to protein based drugs in pharmaceutical industry. Protein drugs are artificially synthesized protein used in treatment of chronic diseases such as cancer, diabetes and CVD. Globally, development the arena of proteomics and nanotechnology, rising incidences of chronic and autoimmune diseases, rise in the awareness among people regarding protein drugs, increasing focus on research and development process, development in drug delivery system, and advantages of protein based drugs such as, high specificity, enhanced efficacy, affinity, solubility, and low incidences of toxicity are the prime growth drivers of protein drugs market. In addition, increase in adoption of protein drugs in emerging economies such as China, India and others, will create new opportunities for global protein drugs market. However, higher cost of the research and development, and complex government approval processes are the key restraints for protein drugs market.

 Protein Drugs Market

Geographically North America dominated global protein drugs market, with approximately half of the market in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing population chronic and autoimmune diseases patient in developing nations such as China, and India in this region. Among all the types, antibody segment has the highest market share in global protein drugs market due to higher prevalence of cancer patients.

This report identifies the global protein drugs market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global protein drugs market.

This report segments global protein drugs market on the basis of type and regional market as follows:
  • Protein Drugs Market, By Type: Antibody Drugs, Peptide Hormones, Blood Products, and Enzymes
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the protein drugs market. Some of the major companies’ profiles in detail are as follows:
  • Eli Lilly
  • Abbott Laboratories
  • UCB Group
  • Schering-Plough Corporation
  • Genentech Inc.
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll